Skip to content
Screener

Alnylam Pharmaceuticals ALNY Common Stock Shares Issued

Common Stock Shares Issued at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
165.6M+4.0%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
197.6M+3.1%
Moderna logo
ModernaMRNA
397M+2.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
205.9M
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
64.8M+29.4%

Other financials

Income statement

See full
Revenue$1.3B+66.9%
Gross profit$992.7M+57.2%
Operating income$231.4M+1,529%
Net income$164.5M+348%
EPS (diluted)$1.21+337%

Balance sheet

See full
Cash & equivalents$1.7B+53.2%
Total debt$256.4M-5.2%
Total equity$1.4B+440%
Total assets$5.6B+21.7%

Cash flow

See full
Operating cash flow$326.7M+113%
CapEx$34.7M+143%
Free cash flow$292.0M+109%

Valuation

See full
Market cap$29.03B-49.5%
Enterprise value$27.58B-51.3%
P/E39.6×
P/S-17.3×

Profitability

See full
Gross margin79.8%-4.1pp
Operating margin20.8%+16.5pp
Net margin15.3%+10.7pp
FCF margin16.5%+14.8pp

Returns & leverage

See full
Return on equity91.4%
Debt / equity0.2×-0.9×
Current ratio3.1×+0.3×

Where this comes from

Reported directly by Alnylam Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 8:11 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001178670-26-000062
Line itemJune 30, 2026December 31, 2025
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.01 par value per share, 250,000 shares authorized; 133,734 shares issued and outstanding as of June 30, 2026; 132,376 shares issued and outstanding as of December 31, 20251,3371,324
Additional paid-in capital7,716,9587,510,473
Accumulated other comprehensive loss(32,138)(20,097)
Accumulated deficit(6,332,039)(6,702,524)
Total stockholders' equity1,354,118789,176

Cover / Front Matter

FAQ

What is Alnylam Pharmaceuticals's common stock shares issued?
Alnylam Pharmaceuticals (ALNY) reported common stock shares issued of 133.7M in Q2 2026.
How has Alnylam Pharmaceuticals's common stock shares issued changed year-over-year?
Alnylam Pharmaceuticals's common stock shares issued increased by 2.1% year-over-year, from 131M to 133.7M.
What is the long-term trend for Alnylam Pharmaceuticals's common stock shares issued?
Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's common stock shares issued has grown at a 2.6% compound annual growth rate (CAGR), from 116.4M to 132.4M.
What does common stock shares issued mean?
The total number of shares that have been authorized and distributed by the corporation since its inception. This includes shares held by the public (outstanding) as well as any shares that the company has repurchased and holds in its treasury. It represents the historical volume of equity capital creation.

Ask your AI about Alnylam Pharmaceuticals's common stock shares issued.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude